biostudies-literatureIsHak WWNCATS NIH HHSNIMH NIH HHS707-16https://www.ebi.ac.uk/biostudies/studies/S-EPMC4777696biostudies-literatureUnknown31(8)<h4>Background</h4>Panic disorder (PD) is highly comorbid with major depressive disorder (MDD) with potential impact on patient-reported outcomes of quality of life (QOL), functioning, and depressive symptom severity.<h4>Methods</h4>Using data from the sequenced treatment alternatives to relieve depression (STAR*D) trial, we compared entry and post-SSRI-treatment QOL, functioning, and depressive symptom severity scores in MDD patients with comorbid PD (MDD+PD) to MDD patients without PD (MDDnoPD). We also compared pre- and posttreatment proportions of patients with severe impairments in quality of life and functioning.<h4>Results</h4>MDD+PD patients experienced significantly lower QOL and functioning and more severe depressive symptoms than MDDnoPD patients at entry. Following treatment wiDepression and anxietyPatient-reported outcomes of quality of life, functioning, and depressive symptom severity in major depressive disorder comorbid with panic disorder before and after SSRI treatment in the star*d trial.PMC4777696N01 MH090003UL1 TR000124N01MH90003Kwock RChristensen SMirocha JPi SElashoff DCohen RMAkopyan ABehjat JWu FIsHak WWPeselow EDfalsePatient-reported outcomes of quality of life, functioning, and depressive symptom severity in major depressive disorder comorbid with panic disorder before and after SSRI treatment in the star*d trial.<h4>Background</h4>Panic disorder (PD) is highly comorbid with major depressive disorder (MDD) with potential impact on patient-reported outcomes of quality of life (QOL), functioning, and depressive symptom severity.<h4>Methods</h4>Using data from the sequenced treatment alternatives to relieve depression (STAR*D) trial, we compared entry and post-SSRI-treatment QOL, functioning, and depressive symptom severity scores in MDD patients with comorbid PD (MDD+PD) to MDD patients without PD (MDDnoPD). We also compared pre- and posttreatment proportions of patients with severe impairments in quality of life and functioning.<h4>Results</h4>MDD+PD patients experienced significantly lower QOL and functioning and more severe depressive symptoms than MDDnoPD patients at entry. Following treatment wi2014-01-01T00:00:00Z2014 Aug2025-05-29T19:45:06.83Z2025-05-29T19:45:06.83ZS-EPMC47776962386118010.1002/da.22152